Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Shares Issued (2017 - 2025)

Seres Therapeutics' Shares Issued history spans 9 years, with the latest figure at $46000.0 for Q3 2025.

  • For Q3 2025, Shares Issued fell 65.67% year-over-year to $46000.0; the TTM value through Sep 2025 reached -$257000.0, up 67.34%, while the annual FY2023 figure was $877000.0, 50.42% down from the prior year.
  • Shares Issued for Q3 2025 was $46000.0 at Seres Therapeutics, down from $184000.0 in the prior quarter.
  • Across five years, Shares Issued topped out at $99.1 million in Q3 2022 and bottomed at -$98.2 million in Q4 2022.
  • The 5-year median for Shares Issued is $188000.0 (2023), against an average of $245588.2.
  • The largest YoY upside for Shares Issued was 56858.62% in 2022 against a maximum downside of 58570.83% in 2022.
  • A 5-year view of Shares Issued shows it stood at $168000.0 in 2021, then plummeted by 58570.83% to -$98.2 million in 2022, then skyrocketed by 98.7% to -$1.3 million in 2023, then skyrocketed by 61.77% to -$487000.0 in 2024, then skyrocketed by 109.45% to $46000.0 in 2025.
  • Per Business Quant, the three most recent readings for MCRB's Shares Issued are $46000.0 (Q3 2025), $184000.0 (Q1 2025), and -$487000.0 (Q4 2024).